Back to search results

Genomic Profiling for Pediatric Leukemia and Related Blood Cancers

This study is looking at the genes of children and young adults (up to age 30) who have leukemia, myelodysplastic syndromes (MDS), or myeloproliferative syndromes (MPS). Genes are like instructions that tell cells how to grow and work. By using "genomic profiling" (a test that looks at these instructions), researchers hope to understand why these diseases develop and why some people respond to treatments differently. This study aims to enroll 300 participants. The main goal is to see how many children with leukemia are enrolled for genomic profiling over three years. The study status is currently unclear, so it's not known if they are actively recruiting.

Study design
This is an observational study, meaning researchers will collect information without giving new treatments. It plans to enroll 300 participants.
What's involved
A sample of your leukemia will be submitted for genomic profiling. The study will also collect follow-up data on your health and how the genomic profiling affected your treatment.
Compensation
Not stated in the trial record.
Follow-up
The study will collect follow-up data on patient outcome and whether genomic profiling influenced treatment, but a specific duration is not mentioned.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04968834

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

Recruiting
Not specifiedUp to 30Observational
Dana-Farber Cancer Institute
~300 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:Genomic profiling

At a glance

Recruiting sites
6 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Patients Enrolled for Genomic Profiling-Pediatric Leukemia
Measured over 3 Years

Conditions

Leukemia
Myelodysplastic Syndromes
Myeloproliferative Syndrome

Explore related trials

LeukemiaMyelodysplastic SyndromeMyeloproliferative syndrome

Where it's being run

8 sites across 7 states
Massachusetts2
Connecticut1
Maine1
New Hampshire1
New York1
Rhode Island1
Vermont1

Study leadership

  • Yana Pikman, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Yana Pikman, MD
[email protected]
(617) 632-4754
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: birth to \< 30 years of age
Diagnosis:
Pathology Criteria:
Specimen Criteria:
Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)

What this trial measures

  • Number of Patients Enrolled for Genomic Profiling-Pediatric Leukemia3 Years

    To perform genomic profiling of pediatric leukemia using clinical genomics platforms and return results to treating oncologist. This objective will be accomplished by enrolling patients and obtaining samples for sequencing and banking. The pathologist-interpreted genomic test results will be returned to the treating oncologist.